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background: Ovarian hyperstimulation syndrome (OHSS) seems to be induced by the ovarian release of vascular endothelial growth
factor (VEGF), which increases vascular permeability. Dopamine agonists inhibit VEGF receptor phosphorylation and thereby decrease vas-
cular permeability.
methods: A randomized, double-blind, placebo-controlled, multicentre study assessing three oral doses (50, 100, 200 mg/day) of the
non-ergot derived dopamine agonist quinagolide started on the day of human chorionic gonadotrophin (hCG) and continued for 17–21
days without dose-titration in comparison to placebo in preventing moderate/severe early OHSS (onset  9 days after hCG administration)
in 182 IVF patients with  20 but less than 30 follicles  10 mm.
results: The incidence of moderate/severe early OHSS was 23% (12/53) in the placebo group and 12% (6/51), 13% (7/52) and 4% (1/
26) in the quinagolide 50, 100 and 200 mg/day groups, respectively. The moderate/severe early OHSS rate was signiﬁcantly lower with all
quinagolide groups combined compared with placebo [P ¼ 0.019; OR ¼ 0.28 (0.09–0.81)]. The incidence of ultrasound evidence of ascites
among patients with no clinical pregnancy was signiﬁcantly reduced from 31% (8/26) with placebo to 11% (8/70) with all quinagolide groups
combined [P ¼ 0.033; OR ¼ 0.29 (0.10–0.88)], although there was no difference for those with clinical pregnancy. Quinagolide did not have
a detrimental effect on pregnancy or live birth rates. The incidence of gastrointestinal and central nervous system adverse events increased
with increasing doses of quinagolide.
conclusions: Quinagolide appears to prevent moderate/severe early OHSS while not affecting treatment outcome. The effect is
more marked in patients who did not achieve a clinical pregnancy. Quinagolide administered in high doses without dose-titration is associated
with poor tolerability.
ClinicalTrials.gov Identiﬁer: NCT00329693.
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Ovarian hyperstimulation syndrome (OHSS) is the most concerning
complication of controlled ovarian hyperstimulation (COH) for
assisted reproduction techniques (ART). It is a broad spectrum of
signs and symptoms that include abdominal distention and discomfort,
enlarged ovaries, ascites and other complications of enhanced vascular
permeability (Golan et al., 1989; Whelan and Vlahos, 2000). The inci-
dence of OHSS reported in the literature varies depending on the data
collection method (registries, clinical trials), the population studied and
the interpretation of the deﬁnitions/classiﬁcations used; however, it is
estimated to be around 6–12%, with the presentation of severe cases
being about 2–4% (Out et al., 1995; Enskog et al., 1999; Devroey
et al., 2009). There are two forms of OHSS, the early with onset
within 9 days after human chorionic gonadotrophin (hCG) adminis-
tration, and the late onset which is believed to be the consequence
of the hCG released by the trophoblast starting 2 days after hCG
administration (Mathur et al., 2000; Papanikolaou et al., 2005). The
latter form is clinically more difﬁcult to manage (Lyons et al., 1994).
The pathophysiology of early OHSS remains unknown but it is clear
that its appearance is mediated by the administration of hCG in COH
cycles. hCG administration leads to vascular permeability enhance-
ment resulting in loss of ﬂuid to the third space and the full blown syn-
drome as a consequence. Vascular endothelial growth factor (VEGF)
has emerged as the main angiogenic factor responsible for increased
vascular permeability (Rizk et al., 1997; Busso et al., 2009). The rel-
evance of VEGF in increased vascular permeability has been demon-
strated using an OHSS animal model (Go ´mez et al., 2002, 2003,
2006). In these assays, it was shown that: (i) vascular permeability is
increased after hCG administration in superovulated animals; (ii)
there is a strong correlation between ovarian mRNAVEGF expression
and vascular permeability (also proving the ovarian origin of VEGF);
(iii) there is an increase of VEGF receptor-2 (VEGFR-2) expression
in the ovaries coincidental in time with maximal vascular permeability,
demonstrating the involvement of VEGF–VEGFR-2 system in OHSS;
(iv) SU5416, a VEGFR-2 inhibitor, can reverse hCG action on vascular
permeability, providing new insights into the development of strategies
to prevent and treat the syndrome based on its pathophysiological
mechanism; (v) the dopamine agonist cabergoline can reverse
VEGFR-2 dependent increased vascular permeability (Go ´mez et al.,
2002, 2003, 2006).
The concept has been tested in humans and it was observed that
cabergoline can signiﬁcantly reduce the incidence of moderate OHSS
as well as pelvic ﬂuid accumulation and hemoconcentration when com-
pared with placebo in oocyte donors at risk of OHSS (Alvarez et al.,
2007b). Implantation and ongoing pregnancy/live birth rates of IVF
patientsatriskofOHSSappeartonotbeaffectedbycabergolineadmin-
istration(Alvarezetal.,2007a; Carizzaet al., 2008),although arandom-
ized, double-blind, placebo-controlled study in which a dopamine
agonist has been used to prevent OHSS in women undergoing ART
has not been performed yet. Cabergoline, however, has been associ-
ated with valvular heart disease when administered chronically in
patientswithParkinson’sdisease(AntoniniandPoewe,2007).Although
theprevalenceofclinicallyrelevantvalvularheartdiseasedidnotappear
increasedwhencabergolineisgivenatlowerdosestopatientswithpro-
lactinomas, such long-term use has also been associated with valvular
ﬁbrotic changes (Kars et al., 2008; Martin et al., 2009).
Quinagolide is a non-ergot-derived dopamine D2 receptor agonist,
with lack of effect on the serotonin (5-hydroxytryptamine [5-HT])
receptor subtype 5-HT2b at relevant concentrations. This may be clini-
cally important as stimulation of 5-HT2b receptors in cardiac valve
tissue may lead to proliferation of ﬁbroblasts (Roth, 2007). The use
of non-ergot-derived dopamine agonist in patients with Parkinson’s
disease does not seem to be associated with an increased prevalence
of heart complications (Zanettini et al., 2007). Dopamine agonists are
also differentiated by their pharmacokinetic proﬁle, as indicated by a
much shorter half-life of quinagolide (17 h) compared with cabergo-
line (63–69 h), thus minimizing exposure during organogenesis
when used in an IVF setting. These two features make quinagolide
an interesting dopamine agonist for use in prevention of OHSS. The
present investigation is the ﬁrst randomized, double-blind study to
evaluate the efﬁcacy of 3 weeks treatment with three different
doses of quinagolide versus placebo in preventing the development
of OHSS in patients undergoing COH for ART.
Materials and Methods
This was a randomized, double-blind, parallel groups, dose-ﬁnding,
placebo-controlled, multicentre study. It was a proof of concept study
assessing the effect of quinagolide in preventing moderate/severe early
OHSS. The primary objective of the study was to identify the effective
doses of quinagolide, including the lowest effective dose, compared with
placebo in preventing moderate/severe early OHSS.
The trial was conducted at seven IVI clinics in Spain (Barcelona, Bilbao,
Madrid, Murcia, Sevilla, Valencia and Vigo) during 2006 and 2007, with the
follow-up period covering collection of pregnancy outcome extending into
2008. The trial was conducted in accordance with the Declaration of
Helsinki and Good Clinical Practice, and the required approvals from the
health authorities and ethics committees were obtained. All participants
gave written, signed, informed consent prior to entering the trial.
Women included in this study were 21–37 years old, had a BMI of 18–
29 kg/m
2 and early follicular phase serum levels of FSH within normal
limits (1–12 IU/l) as well as a uterus consistent with expected normal
function and presence of both ovaries. They had been infertile for at
least 1 year, and were currently undergoing a COH cycle for IVF/ICSI
in which they presented with ovarian response suggestive of being at
risk of developing OHSS because of the presence of at least 20 follicles
of 10 mm or greater on the day of hCG administration. Patients at very
high risk of OHSS, presenting with more than 30 follicles and/or serum
E2 of  6000 pg/ml (local laboratory) were not included in this study as
cycle cancellation in such patients would be appropriate. If coasting or
other preventive measures for managing OHSS had been applied, the
patient could not enter the trial. Women with any clinically signiﬁcant sys-
temic disease, endocrine or metabolic abnormalities or history of recur-
rent miscarriage were excluded from participation. Also, women with
hypertension, hypotension, orthostatic hypotension, recurrent syncope
or any contra-indication to the use of gonadotrophins or dopamine ago-
nists were prohibited from inclusion. Screening could be initiated at any
time point during the COH cycle, but the last checks for eligibility could
only be made on the day of hCG administration (day of randomization).
Subjects were randomized in a 1:1:1:1 fashion to one of the following
four treatment groups: quinagolide 50 mg/day, quinagolide 100 mg/day,
quinagolide 200 mg/day or placebo. A computer-generated randomization
list was prepared for each center by a statistician not involved in the trial,
and based on this the clinics were provided with individual code envelopes
that were sealed in order to conceal the treatment group allocation.
The block size was not disclosed during the study. At the time of
996 Busso et al.randomization, the investigator assigned the subject to the lowest available
number and she was thereby allocated to the corresponding treatment
group. The study was double-blind; subjects as well as staff at clinics and
trial sponsor were blinded to treatment allocation.
Treatment consisted of four tablets (combination of indistinguishable
quinagolide 50 mg and placebo tablets) to be taken orally once daily. On
the ﬁrst day of dosing, the tablets were taken at least 2 h before the
hCG injection; while on subsequent days administration occurred at
bedtime. The dose-titration approach used for quinagolide in patients
with hyperprolactinemia was not applied given the acute onset of OHSS
after hCG administration. Treatment was continued until the day before
the serum hCG test which took place 17+2 days after oocyte retrieval
(OR). All subjects received a single dose of hCG (Ovitrelle 250 mg SC,
Merck-Serono, Geneva, Switzerland) to trigger ﬁnal maturation when
 2 follicles of  18 mm were observed. OR took place 36+2 h after
hCG administration and transfer of 1–2 embryos was done on Day 3
or Day 5–6 after OR. Luteal support was provided with vaginal progester-
one (Utrogestan, SEID Laboratories, Barcelona, Spain), 200 mg twice daily
from the day after OR to negative bhCG test or to the day of clinical preg-
nancy assessment. Clinical pregnancy was deﬁned as at least one intrauter-
ine gestational sac with fetal heart beat documented by transvaginal
ultrasound 5 weeks after embryo transfer (Fig. 1). As post-study
follow-up, information on ongoing pregnancy (at least one intrauterine
viable fetus documented by transvaginal ultrasound 10–11 weeks after
embryo transfer) and pregnancy outcome (live birth and neonatal safety)
was collected for all subjects with clinical pregnancy at the end of the
study. Furthermore, the post-study follow-up also covered patients who
discontinued from the trial after exposure to trial medication and for
whom pregnancy data were available (hereafter ‘outside of trial’).
Evaluation of early OHSS signs/symptoms was performed on the day of
OR, Day OR þ3 and Day OR þ6, corresponding to the ﬁrst 9 days after
hCG administration. Evaluation of late OHSS signs/symptoms, i.e. onset
more than 9 days after hCG administration, was performed on Day OR
þ10 (+2) as well as on the day of serum bhCG test and the day of clinical
pregnancy assessment. Transvaginal ultrasound to measure pelvic ﬂuid
pockets, body measurements and blood samples were taken at each
visit. All individual signs/symptoms of OHSS were assessed and OHSS
was classiﬁed as moderate or severe using Golan’s classiﬁcation system
(Golan et al., 1989) with certain modiﬁcations and speciﬁcations.
Moderate OHSS was deﬁned as abdominal distension and discomfort,
enlarged ovaries and ultrasound evidence of ascites. Nausea, vomiting
and diarrhoea were not included in the interpretation of moderate
OHSS, as these symptoms are also among the undesirable effects of dopa-
mine agonists and therefore could not with certainty be attributed to
OHSS; thus being less appropriate parameters for evaluation of OHSS inci-
dence. Ultrasound evidence of ascites was quantiﬁed by measuring the size
of the ﬂuid pockets in the pelvis. This parameter was ﬁrst analyzed using
peritoneal ﬂuid volume  9c m
2 based on data from a study in oocyte
donors (Alvarez et al., 2007b), but this arbitrarily selected cut-off did
not discriminate among groups in IVF/ICSI patients with subsequent
embryo transfer and potential pregnancy and a cut-off of  24 cm
2 was
used for the ﬁnal analysis. Severe OHSS was deﬁned as features of mod-
erate OHSS plus clinical evidence of ascites and/or hydrothorax or
breathing difﬁculties; and/or by the presence of change in blood
volume, increased blood viscosity due to haemoconcentration, coagulation
abnormalities and diminished renal perfusion and function. Finally, it was
speciﬁed that the symptoms of OHSS did not have to be present at the
same visit, however, all symptoms were to be present in the period of
early OHSS ( 9 days after hCG administration) or the period of late
OHSS (.9 days after hCG administration).
The primary end-point was the percentage of subjects with a moder-
ate/severe early OHSS (onset  9 days after hCG administration). The
sample size calculation assumed comparison of two binomial proportions
using a two-sided signiﬁcance level (a) of 0.05 and a power of 80%. On the
basis of interim data from a study in oocyte donors at risk of OHSS
(Alvarez et al., 2007b), in which moderate/severe OHSS was reported
for 24% (7/29) and 52% (13/25) in the dopamine agonist and placebo
groups, respectively, 50 subjects per group were required for the
present trial to show a signiﬁcant difference between the highest dose
of quinagolide and placebo. Test for overall treatment effect and compari-
son between each dose of quinagolide versus placebo were based on the
likelihood ratio test (in the full model) with a signiﬁcance level of 0.05. Pre-
speciﬁed analyses were also conducted for all quinagolide dose levels com-
bined versus placebo. In addition to the primary end-point, treatment
comparisons were also made for secondary trial end-points which
included the proportion of patients with ultrasound evidence of ascites,
peritoneal ﬂuid volume, the proportion of patients with moderate/
severe late OHSS, clinical pregnancy rate and adverse event frequency.
The main analysis of treatment effect was adjusted, estimated using a logis-
tic regression analysis including the factors ‘treatment group’ and ‘centre’
and moderate/severe early OHSS as the response. Treatment differences
were presented with odds ratios and two-sided 95% conﬁdence interval
and corresponding P-values. Furthermore, to assess dose-linearity a
Cochrane–Armitage linear trend test was performed. The statistical
Figure 1 Trial schedule and overview.
Quinagolide in prevention of moderate/severe early OHSS 997package from SAS version 9.1 was used. No adjustment for multiplicity to
correct for repeated testing was applied to the primary end-point due to
the hierarchical testing strategy or to the secondary variables. The analyses
are based on the intention-to-treat (ITT) population, i.e. all randomized,
unless otherwise indicated. On the basis of the trial ﬁndings, subgroup ana-
lyses of efﬁcacy parameters were conducted according to pregnancy
status, i.e. whether the patient had a clinical pregnancy in the trial cycle
or not. Pregnancy and live birth data were analyzed for the population con-
sisting of patients who had undergone embryo transfer.
During the trial, a safety committee monitored the overall frequency of
adverse events while remaining blinded to treatment allocation. When noti-
cing a potential safety signal in the form of a high total frequency of adverse
events, an independent statistician was requested to perform an unplanned
interim analysis. The analysis and the dissemination of results were handled
in a manner that maintained blinding to the individual treatment allocation
of subjects, investigators and other personnel at the clinic as well as
Sponsor staff. Thus, the double-blind design of the trial remained intact.
Results
A total of 182 IVF/ICSI patients were randomized to the trial, with the
following distribution to the four treatment groups: 53 (29%) were
randomized to placebo, 51 (28%) to quinagolide 50 mg/day, 52
(29%) to quinagolide 100 mg/day and 26 (14%) to quinagolide
200 mg/day. Randomization to the quinagolide 200 mg/day group
was stopped after inclusion of 97 subjects into the trial due to poor
tolerability within the ﬁrst 1–3 days of treatment with quinagolide
200 mg/day when administered without dose-titration. The distri-
bution of patients to the four treatment groups was balanced within
each center. Table I summarizes the main demographics and baseline
characteristics of the trial population. There were no statistically signiﬁ-
cant differences between treatment groups with respect to age, body
weight or infertility reason. The treatment groups were also compar-
able with respect to serum E2 and number of follicles on the day of
hCG administration as well as number of oocytes retrieved. The
mean number of follicles  10 mm ranged from 23.2 to 25.0 in the
four treatment groups, and an average of 21.0 oocytes were retrieved
(Table I). The ﬂow of participants is illustrated in Fig. 2, which depicts
the number of patients attending each trial visit.
The serum prolactin concentrations over time are illustrated in
Fig. 3. A rapid and dose-dependent reduction in serum prolactin
levels was observed with quinagolide. On the day of OR (before
administration of the third dose of quinagolide), the mean prolactin
concentration was 30.7 ng/ml in the placebo group, compared with
10.8, 5.4 and 2.9 ng/ml in the quinagolide 50, 100 and 200 mg/day
groups, respectively (Fig. 3).
Moderate/severe early OHSS occurred at the following frequencies:
23% (12/53) for placebo, 12% (6/51) for quinagolide 50 mg/day, 13%
(7/52) for quinagolide 100 mg/day and 4% (1/26) for quinagolide
200 mg/day(TableII).Whencombiningthethreedoselevels,quinagolide
was associated with a signiﬁcant [P ¼ 0.019; OR ¼ 0.28 (0.09–0.81)]
decrease in the frequency of moderate/severe early OHSS. Concerning
the individual doselevels ofquinagolide, the 200 mg/day group had a sig-
niﬁcantly [P ¼ 0.046; OR ¼ 0.11 (0.01–0.96)] lower proportion of
patients with moderate/severe early OHSS compared with placebo.
The 12 and 13% rates of moderate/severe early OHSS with the lower
doses of 50 and 100 mg/day were not signiﬁcantly different from the
23% rate observed with placebo [P ¼ 0.142; OR ¼ 0.43 (0.14–1.32)
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998 Busso et al.and P ¼ 0.161; OR ¼ 0.45 (0.15–1.37)], respectively. The combination
of the quinagolide 100 and 200 mg/day groups yielded a frequency of
moderate/severe early OHSS of 10% (8/78) [P ¼ 0.026; OR ¼ 0.22
(0.06–0.83)]; the corresponding rate for the combination of the 50 and
100 mg/day dose levels was 13% (13/103) [P ¼ 0.086; OR ¼ 0.44
(0.17–1.12)].
The effect of quinagolide appeared to be consistent among patients
following a GnRH agonist (n ¼ 148) or GnRH antagonist (n ¼ 34)
down-regulation protocol with reductions in moderate/severe early
OHSS rate from 20–33% in the placebo group to 0–6% in the quina-
golide 200 mg/day group.
Early OHSS Grade 4 or 5 occurred for 6% (3/53) of the subjects in
the placebo group and 2% (1/51) in the quinagolide 50 mg/day group,
and none of the subjects in the 100 and 200 mg/day groups experi-
enced severe early OHSS (Table II). The incidence of patients with
ultrasound evidence of ascites within the initial 9 days after hCG
was signiﬁcantly [P ¼ 0.027; OR ¼ 0.09 (0.01–0.77)] reduced from
28% (15/53) in the placebo group to 4% (1/26) in the quinagolide
200 mg/day group.
Clinical pregnancy was found to be a statistically signiﬁcant factor
(P ¼ 0.044) in the logistic regression model analyzing moderate/
severe early OHSS, and the results are therefore also presented sep-
arately for subjects who achieved a clinical pregnancy in the study cycle
and those who did not. The incidence of moderate/severe early
OHSS among subjects who did not obtain a clinical pregnancy was sig-
niﬁcantly reduced from 23% (6/26) with placebo to 4% (3/70) with all
groups of quinagolide combined [P ¼ 0.011; OR ¼ 0.15 (0.03–0.65)]
(Fig. 4a). In patients who had a documented clinical pregnancy in the
study cycle the incidence of moderate/severe early OHSS was not sig-
niﬁcantly different among any of the study groups (individually or com-
bined; Fig. 4b). With respect to ultrasound evidence of ascites within
the initial 9 days after hCG administration, quinagolide was able to
reduce the incidence of this OHSS sign among the patients who did
Figure 2 Disposition of patients by trial visit.
N indicates the number of patients attending the trial visits/undergoing the trial procedures. Patients who stopped trial medication prematurely were
discontinued from the trial, but may have undergone procedures related to the controlled ovarian hyperstimulation cycle (e.g. OR and embryo trans-
fer) outside the trial; these patients are not included in Fig 2. End-of-trial visits were scheduled both for patients who completed the trial and patients
who discontinued early (three patients were lost to follow-up after negative bhCG test).
Figure 3 Mean serum prolactin concentrations (ng/ml) during the
trial.
Quinagolide in prevention of moderate/severe early OHSS 999not obtain a clinical pregnancy from 31% (8/26) in the placebo group
to 11% (8/70) with all groups of quinagolide combined [P ¼ 0.033;
OR ¼ 0.29 (0.10–0.88)] (Fig. 4c). Among the patients with a clinical
pregnancy, there was no signiﬁcant difference between quinagolide
and placebo with respect to the presence of ultrasound evidence of
ascites (Fig. 4d). Peritoneal ﬂuid over time followed a dose–response
pattern in patients with no clinical pregnancy although there was no
relationship between peritoneal ﬂuid accumulation and the use of qui-
nagolide in patients with a clinical pregnancy (Fig. 5a and b).
The average number of embryos transferred ranged from 1.9 to 2.0
in the four treatment groups. Transfer of three embryos occurred in
one subject in each treatment group. The clinical pregnancy rates
were comparable across treatment groups. Among subjects with
embryo transfer, the clinical pregnancy rate was 57% in the placebo
group and in the range 49–65% in the quinagolide groups with no
dose–response pattern (Table II). The frequency of moderate/
severe late OHSS, i.e onset .9 days after hCG administration, was
4% (2/53) in the placebo group and 4% (2/51), 6% (3/52) and 4%
(1/26) in the quinagolide 50, 100 and 200 mg/day groups, respect-
ively. All subjects with moderate/severe late OHSS had a clinical
pregnancy, of which 50% were multiple pregnancies.
No subjects in the placebo group discontinued because of adverse
events, however this was the case for 6% (3/51), 13% (7/52) and 27%
(7/26) in the quinagolide 50, 100 and 200 mg/day groups, respect-
ively; mainly due to gastrointestinal and central nervous system
adverse events. The most common adverse events in the trial were
vomiting, nausea, dizziness and somnolence, which all were reported
at a higher frequency with quinagolide compared with placebo
(Table III). The frequency of nausea, vomiting and somnolence
increased with increasing quinagolide dose, although dizziness
occurred at a similar frequency in all three quinagolide dose groups.
The majority of gastrointestinal adverse events occurred after the
ﬁrst and second administration of investigational medicinal product,
with a dose-dependent increase in the quinagolide groups. By the
end of the ﬁrst week of treatment, the onset of new gastrointestinal
adverse events was similar across treatment groups (Fig. 6a). Similarly,
most of the central nervous system adverse events were reported on
the day of the ﬁrst administration, and with the frequency increasing
with the dose of quinagolide. The frequency of nervous system
adverse events with onset after the initial 1–3 days of treatment
was similar for placebo and quinagolide (Fig. 6b).
Post-study follow-up information was collected for all 86 subjects
with a clinical pregnancy documented at the trial visit and their 119
fetuses. In addition, nine subjects who discontinued from the trial
after exposure to quinagolide/placebo but who had embryo transfer
outside the trial contribute with safety post-study follow-up data. The
ongoing pregnancy and live birth rates were similar among treatment
groups(TableII).Therewasonecaseofmiscarriagebetweentheclinical
and the ongoing pregnancy assessments in the placebo group and one
patient in the quinagolide 100 mg/day group was lost to follow-up
after conﬁrmed ongoing pregnancy. The majority of neonates were
born at term and there were no very premature deliveries. The birth-
weight and length were comparable across treatment groups. Congeni-
tal malformations were recorded for none of the 38 neonates in the
placebo group, 3 of the 30 neonates in the quinagolide 50 mg/day
group (syndactyly, hydrocephalus, congenital cystic kidney disease), 3
of the 38 neonates in the quinagolide 100 mg/day group (two cases of
double ureter, trisomy 21) and none of the 17 neonates in the quinago-
lide200 mg/daygroup.Onthebasisofateratologicalreviewbyaninde-
pendent expert in embryology development, the double ureter cases
...........................................................
.............................................................................................................................................................................................
Table II Overview of main end-points.
Placebo Quinagolide P
a odds ratio [95% conﬁdence interval]
50 mg/day 100 mg/day 200 mg/day
Subjects randomised (ITT) n ¼ 53 n ¼ 51 n ¼ 52 n ¼ 26
OHSS and symptoms
Moderate/severe early OHSS 23% (12) 12% (6) 13% (7) 4% (1) P ¼ 0.019/OR ¼ 0.28 [0.09; 0.81]
Severe early OHSS, Grade 4/5 6% (3) 2% (1) 0% (0) 0% (0) P ¼ 0.075/OR ¼ 0.13 [0.00; 1.67]
Ultrasound evidence of ascites 28% (15) 22% (11) 19% (10) 4% (1) P ¼ 0.028/OR ¼ 0.33 [0.13; 0.89]
Treatment outcome parameters (within the trial)
Embryo transfer during the trial n¼ 47 n ¼ 45 n ¼ 40 n ¼ 19
Positive bhCG 70% (33) 56% (25) 75% (30) 63% (12) P ¼ 0.578/OR ¼ 0.77 [0.34; 1.70]
Clinical pregnancy 57% (27) 49% (22) 65% (26) 58% (11) P ¼ 0.470/OR ¼ 1.34 [0.62; 2.87]
Implantation rate 44% 32% 49% 39% P ¼ 0.538
Post-trial follow-up
Embryo transfer outside the trial
b n ¼ 1 n ¼ 1 n ¼ 4 n ¼ 3
Embryo transfer, total n ¼ 48 n ¼ 46 n ¼ 44 n ¼ 22
Ongoing pregnancy 56% (27) 50% (23) 68% (30) 64% (14) P ¼ 0.862/OR ¼ 1.11 [0.53; 2.31]
Live birth 56% (27) 50% (23) 64% (29) 64% (14) P ¼ 0.863/OR ¼ 1.07 [0.51; 2.22]
ITT, intention-to-treat; OHSS, ovarian hyperstimulation syndrome.
aP-values are for the analysis of all quinagolide groups combined versus placebo.
bActivities that took place after the patient had discontinued/withdrawn from the trial.
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judged by the investigator to be unrelated to treatment.
Discussion
The oral administration of a dopamine agonist to oocyte donors and
IVF/ICSI patients provides a potential preventive therapeutic tool in
current ART practice, as early OHSS is an undesirable complication
that should be avoided. This is the ﬁrst randomized, double-blind,
placebo-controlled trial testing several doses of a dopamine agonist
in ART patients at risk of OHSS. The study demonstrated that quina-
golide at a dose of 200 mg/day can prevent moderate/severe early
OHSS in IVF patients and suggested that also lower doses of quinago-
lide may be efﬁcacious.
The overall incidence of moderate/severe early OHSS observed in
this trial was lower than expected, with an incidence of 23% in
the placebo group compared with 52% reported in the trial used
for the sample size calculations (Alvarez et al., 2007b). Possible expla-
nations for this include differences in trial populations and method-
ology. Although the follicular response required for participation was
the same in the two trials, a further restriction was made in the single-
centre study, which only reported data for the subset of subjects who
had at least 20 oocytes retrieved rather than for all subjects treated
(Alvarez et al., 2007b). Furthermore, the cut-off of peritoneal ﬂuid
volume used to deﬁne ultrasound evidence of ascites plays a role in
the frequency of moderate/severe OHSS, and in this respect the
9c m
2 cut-off used in the previous trial (Alvarez et al., 2007b) will
have contributed to a higher rate than when applying 24 cm
2 as
done in this trial. Despite that the OHSS rates in the placebo
Figure 4 Moderate/severe early OHSS rate according to the patient’s pregnancy status in the trial cycle; no clinical pregnancy (a) and clinical preg-
nancy (b); and percentage of patients with ultrasound evidence of ascites within the initial 9 days after hCG administration according to the patient’s
pregnancy status in the trial cycle; no clinical pregnancy (c) and clinical pregnancy (d).
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note that the relative reduction in OHSS rate in the dopamine agonist
group versus the placebo group was similar in the two studies (around
50%).
Although other studies have indicated a reduction of the incidence
of OHSS or ultrasound evidence of ascites with cabergoline (Alvarez
et al., 2007b; Carizza et al., 2008) the present study provides for
the ﬁrst time dose–response information and the identiﬁcation of
clinical pregnancy as a major confounding factor in the interpretation
of the efﬁcacy data. In patients who did not become pregnant, quina-
golide prevented moderate/severe OHSS by decreasing the incidence
of ascites in a dose–response fashion. This ﬁnding leads to the hypoth-
esis that in women who get pregnant, either higher doses of the dopa-
mine agonist is required to prevent OHSS and/or other vascular
permeability parameters and angiogenesis mediators, less inﬂuenced
by dopamine agonists, may be present. In patients who did not get
pregnant, quinagolide treatment had a signiﬁcant effect on reducing
the incidence of ultrasound evidence of ascites. Abdominal ﬂuid
accumulation over time shows two completely different behaviors in
pregnant and non-pregnant patients. Among the subjects who did
not obtain a clinical pregnancy in the trial cycle, the highest volume
of peritoneal ﬂuid observed within the ﬁrst 9 days of treatment was
reduced by 50% in the quinagolide 200 mg/day group compared
with placebo.
The population included in the trial were women developing at least
20 follicles during COH, but not more than 30, and with serum estra-
diol less than 6000 pg/ml after end of stimulation. Thus, they were at
risk of moderate OHSS, but only to a lesser extent at risk of severe
OHSS. Nevertheless, the ﬁndings on severe early OHSS are also sup-
portive as none of the subjects in the quinagolide 100 and 200 mg/day
groups experienced severe early OHSS, although this was the case for
three subjects in the placebo group and one in the quinagolide 50 mg/
day group.
Late OHSS is associated with the most severe forms of OHSS that
lead to severe complications and hospitalization (Mathur et al., 2000;
Papanikolaou et al., 2005). The present study included monitoring of
late OHSS, although it was not designed for evaluation of late
OHSS, as the participants were selected based on being at risk of
early OHSS. Consistent with the data on cabergoline in COH patients
(Carizza et al., 2008), quinagolide did not have an effect on the fre-
quency of moderate/severe late OHSS. This is in line with the
current thinking that late OHSS has a different pathophysiology than
early OHSS, and further supported by the observation that all late
OHSS cases occurred in patients with a clinical pregnancy. It seems
that either the high levels of hCG released by the trophoblast, and/
Figure 5 Mean peritoneal ﬂuid (cm
2) according to the patient’s
pregnancy status in the trial cycle; no clinical pregnancy (a) and clinical
pregnancy (b).
.....................................................
........................................................................................
Table III Frequent adverse events.
Placebo Quinagolide
50 mg/day 100 mg/day 200 mg/day
Subjects
randomized
(ITT)
n ¼ 53 n ¼ 51 n ¼ 52 n ¼ 26
Nausea 25% (13) 35% (18) 50% (26) 69% (18)
Dizziness 15% (8) 41% (21) 52% (27) 42% (11)
Somnolence 13% (7) 25% (13) 33% (17) 42% (11)
Diarrhoea 13% (7) 12% (6) 13% (7) 12% (3)
Vomiting 8% (4) 24% (12) 71% (37) 69% (18)
Abdominal
pain lower
8% (4) 8% (4) 8% (4) 4% (1)
Headache 6% (3) 10% (5) 10% (5) 12% (3)
Abdominal
distension
6% (3) 0% 2% (1) 0%
Flatulence 4% (2) 8% (4) 2% (1) 4% (1)
Abdominal
pain upper
4% (2) 6% (3) 0% 0%
Syncope 0% 2% (1) 8% (4) 12% (3)
ITT, intention-to-treat.
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that achieve pregnancy, resulting in a cascade of events leading to
increased vascular permeability that cannot be avoided by the doses
of oral dopamine agonist preparations tested so far. There is,
however, evidence in the literature that using intravenous dopamine
in severely hyperstimulated women increased urinary output and
improved the OHSS symptoms (Ferraretti et al., 1992). Although
the mechanism of dopamine action was not established in this
pioneer report, it is now known from studies in rodents and
humans that dopamine agonists are potent inhibitors of VEGF-
mediated increased vascular permeability by inhibition of VEGF-R2
phosphorylation and speciﬁcally act at the ovarian level (Gomez
et al., 2006; Alvarez et al., 2007b). Future studies should establish
whether intravenous dopamine is the treatment of choice in late
OHSS that appears in pregnant patients.
The major concern with the use of dopamine agonists in ART is that
therapies which could reduce vascular permeability may also decrease
embryo implantation as angiogenesis would be reduced. In line with
reports that cabergoline does not appear to affect treatment
outcome (Alvarez et al., 2007b; Carizza et al., 2008), clinical pregnancy
rates were comparable in the quinagolide and placebo groups, indicat-
ing that administration of quinagolide for 3 weeks after hCG adminis-
tration does not have a detrimental impact on treatment success. It is
reassuring that there was no detrimental dose–response in pregnancy
or live birth rates and that even the highest dose of quinagolide did not
negatively inﬂuence the patients’ probability of conceiving. The neo-
natal health data from the offspring in this trial did not raise any
safety concerns associated with the use of quinagolide during the
initial 3 weeks after OR. There was no dose–response pattern in
the congenital abnormalities reported as part of the post-trial safety
follow-up; and they were considered random occurrences with very
unlikely biological plausibility. The short half-life of quinagolide
(17 h) compared with other dopamine agonists should minimize
exposure to the compound during organogenesis. Non-clinical repro-
ductive toxicology studies with quinagolide have provided no evidence
of embryotoxic or teratogenic potential and the clinical data from
post-marketing surveillance on exposure to quinagolide during preg-
nancy have suggested incidences of congenital abnormalities of
around 4% which are in line with the 4% estimated for the general
population (Pregnancy Outcomes Working Group of the FDA Preg-
nancy Labeling Taskforce in the Center for Drug Evaluation and
Research and the Center for Biologics Evaluation and Research at
the Food and Drug Administration, 2005).
Nausea, vomiting, dizziness and somnolence were more frequent in
quinagolide-treated patients than controls with placebo, and they
appeared in a dose-dependant manner. However, most events reﬂect-
ing an effect of quinagolide on the gastrointestinal and central nervous
systems occurred within 1–3 days of administration, and mainly after
the ﬁrst dose. The 200 mg dose of quinagolide was the most effective
in preventing moderate/severe early OHSS, but this dose was associ-
ated with poor tolerability when administered without dose-titration.
Future studies should investigate if high doses of quinagolide when
administered with dose-titration have an acceptable patient tolerability
or if lower doses in a ﬁxed regimen would be suitable strategies for
prevention of early onset of OHSS.
In summary, the present study suggests that quinagolide in a ﬁxed
regimen reduces the frequency of moderate/severe early OHSS
without compromising pregnancy or treatment outcome. The treat-
ment effect is more marked in patients who did not obtain a clinical
pregnancy. When administered without dose-titration, quinagolide at
high doses is associated with poor tolerability, although the incidence
of adverse events declines after the initial days of treatment. The ﬁnd-
ings from this trial may be especially relevant for oocyte donation pro-
grams and for patients with postponed embryo transfer.
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